Skip to main navigation Skip to search Skip to main content

Fifty two-week efficacy and safety results from SPIRIT-P1: A Phase 3 study of ixekizumab in patients with active psoriatic arthritis. 92nd National Congress of the Italian Society of Dermatology Medical, Surgical, Beauty, and Sexually Transmitted Diseases (SIDeMaST), Sorrento, Italy, May 2017.

Research output: Contribution to conference › Poster

Original languageAmerican English
StatePublished - May 2017
Event92nd National Congress of the Italian Society of Dermatology Medical, Surgical, Beauty, and Sexually Transmitted Diseases (SIDeMaST) -
Duration: May 1 2017 → …

Conference

Conference92nd National Congress of the Italian Society of Dermatology Medical, Surgical, Beauty, and Sexually Transmitted Diseases (SIDeMaST)
Period05/1/17 → …

Disciplines

  • Rheumatology

Cite this